Award

REGN-COV2 SUPPLY AGREEMENT FOR PANDEMIC PURPOSES

BUSINESS ENERGY AND INDUSTRIAL STRATEGY

This public procurement record has 1 release in its history.

Award

01 Apr 2021 at 17:14

Summary of the contracting process

The procurement process involves the Business Energy and Industrial Strategy as the contracting authority, seeking to establish a supply agreement for REGN-COV2 aimed at pandemic purposes. This tender, classified under the pharmaceutical products category, was initiated on 1st April 2021 and has reached the award stage, with the contract signed on 5th March 2021. The procurement method used was a limited one, allowing for direct award due to extreme urgency related to the ongoing global health crisis. The procurement is located in the UK, highlighting the immediate need for effective pandemic response solutions.

This tender presents significant opportunities for businesses, particularly those specialising in pharmaceutical research, supply chain logistics, and health-related product manufacturing. Companies that can meet the urgent demand for COVID-19 treatment solutions are particularly well-suited to compete in this procurement process. Engaging in such contracts can enhance a business's portfolio, improve market presence, and contribute to addressing critical public health needs during this challenging time.

Find more tenders on our Open Data Platform.
How relevant is this notice?

D3 Tenders Premium

Win More Public Sector Contracts

AI-powered tender discovery, pipeline management, and market intelligence — everything you need to grow your public sector business.

Notice Title

REGN-COV2 SUPPLY AGREEMENT FOR PANDEMIC PURPOSES

Notice Description

Procurement for REGN-COV2.

Lot Information

Lot 1

Procurement for REGN-COV2. Additional information: Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vendors and (iii) impact fair competition between vendors .

Procurement Information

Our position, after reviewing the advice from counsel, is that under the unforeseen current global public health crisis there is a strong argument that the direct award of a contract with Roche is compliant with current PCR regulations in respect to section 32(2)(c). Firstly, the urgent award to Roche is strictly necessary to prevent significant loss of life, disease, and protracted periods of continued economic stress. Delay in acquiring binding assurances to reserves of antibody doses would pose an imminent risk for long term procurement of a antibody to combat the Covid-19 pandemic. Therefore, the UKs adoption of a protectionist approach to acquiring the Regeneron antibody via a direct award is fully justified under PCR regulation 32(2)(c).

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-02a25c
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/006891-2021
Current Stage
Award
All Stages
Award

Procurement Classification

Notice Type
Award Notice
Procurement Type
Standard
Procurement Category
Goods
Procurement Method
Limited
Procurement Method Details
Award procedure without prior publication of a call for competition
Tender Suitability
Not specified
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products


CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
£1

Notice Dates

Publication Date
1 Apr 20214 years ago
Submission Deadline
Not specified
Future Notice Date
Not specified
Award Date
5 Mar 20214 years ago
Contract Period
Not specified - Not specified
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Cancelled
Awards Status
Active
Contracts Status
Active

Contracting Authority (Buyer)

Main Buyer
BUSINESS ENERGY AND INDUSTRIAL STRATEGY
Contact Name
Not specified
Contact Email
vtfcontracts@beis.gov.uk
Contact Phone
Not specified

Buyer Location

Locality
LONDON
Postcode
SW1H 0ET
Post Town
South West London
Country
England

Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI3 Inner London - West
Small Region (ITL 3)
TLI35 Westminster and City of London
Delivery Location
TLL Wales

Local Authority
Westminster
Electoral Ward
St James's
Westminster Constituency
Cities of London and Westminster

Supplier Information

Number of Suppliers
1
Supplier Name

ROCHE PRODUCTS

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

Download

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-02a25c-2021-04-01T18:14:41+01:00",
    "date": "2021-04-01T18:14:41+01:00",
    "ocid": "ocds-h6vhtk-02a25c",
    "initiationType": "tender",
    "tender": {
        "id": "4964/03/2021",
        "legalBasis": {
            "id": "32014L0024",
            "scheme": "CELEX"
        },
        "title": "REGN-COV2 SUPPLY AGREEMENT FOR PANDEMIC PURPOSES",
        "status": "complete",
        "classification": {
            "scheme": "CPV",
            "id": "33600000",
            "description": "Pharmaceutical products"
        },
        "mainProcurementCategory": "goods",
        "description": "Procurement for REGN-COV2.",
        "lots": [
            {
                "id": "1",
                "description": "Procurement for REGN-COV2. Additional information: Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vendors and (iii) impact fair competition between vendors .",
                "awardCriteria": {
                    "criteria": [
                        {
                            "type": "price"
                        }
                    ]
                },
                "hasOptions": false,
                "status": "cancelled"
            }
        ],
        "items": [
            {
                "id": "1",
                "deliveryAddresses": [
                    {
                        "region": "UKL"
                    }
                ],
                "relatedLot": "1"
            }
        ],
        "procurementMethod": "limited",
        "procurementMethodDetails": "Award procedure without prior publication of a call for competition",
        "coveredBy": [
            "GPA"
        ],
        "procurementMethodRationaleClassifications": [
            {
                "scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
                "id": "D_EXTREME_URGENCY",
                "description": "Extreme urgency brought about by events unforeseeable for the contracting authority/entity and in accordance with the strict conditions stated in the directive"
            }
        ],
        "procurementMethodRationale": "Our position, after reviewing the advice from counsel, is that under the unforeseen current global public health crisis there is a strong argument that the direct award of a contract with Roche is compliant with current PCR regulations in respect to section 32(2)(c). Firstly, the urgent award to Roche is strictly necessary to prevent significant loss of life, disease, and protracted periods of continued economic stress. Delay in acquiring binding assurances to reserves of antibody doses would pose an imminent risk for long term procurement of a antibody to combat the Covid-19 pandemic. Therefore, the UKs adoption of a protectionist approach to acquiring the Regeneron antibody via a direct award is fully justified under PCR regulation 32(2)(c)."
    },
    "awards": [
        {
            "id": "006891-2021-4964/03/2021-1",
            "relatedLots": [
                "1"
            ],
            "title": "REGN-COV2 SUPPLY AGREEMENT FOR PANDEMIC PURPOSES",
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-FTS-11150",
                    "name": "Roche Products Limited"
                }
            ]
        }
    ],
    "parties": [
        {
            "id": "GB-FTS-5606",
            "name": "Business Energy and Industrial Strategy",
            "identifier": {
                "legalName": "Business Energy and Industrial Strategy"
            },
            "address": {
                "streetAddress": "1 Victoria Street",
                "locality": "London",
                "region": "UK",
                "postalCode": "SW1H0ET",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "email": "VTFContracts@beis.gov.uk"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.gov.uk/government/organisations/department-for-business-energy-and-industrial-strategy",
                "classifications": [
                    {
                        "scheme": "TED_CA_TYPE",
                        "id": "MINISTRY",
                        "description": "Ministry or any other national or federal authority, including their regional or local subdivisions"
                    },
                    {
                        "scheme": "COFOG",
                        "id": "01",
                        "description": "General public services"
                    }
                ]
            }
        },
        {
            "id": "GB-FTS-11150",
            "name": "Roche Products Limited",
            "identifier": {
                "legalName": "Roche Products Limited"
            },
            "address": {
                "locality": "Welwyn Garden City",
                "region": "UKL",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-11151",
            "name": "Department of Business, Energy and Industrial Strategy",
            "identifier": {
                "legalName": "Department of Business, Energy and Industrial Strategy"
            },
            "address": {
                "locality": "London",
                "countryName": "United Kingdom"
            },
            "roles": [
                "reviewBody"
            ]
        }
    ],
    "buyer": {
        "id": "GB-FTS-5606",
        "name": "Business Energy and Industrial Strategy"
    },
    "contracts": [
        {
            "id": "006891-2021-4964/03/2021-1",
            "awardID": "006891-2021-4964/03/2021-1",
            "title": "REGN-COV2 SUPPLY AGREEMENT FOR PANDEMIC PURPOSES",
            "status": "active",
            "value": {
                "amount": 1,
                "currency": "GBP"
            },
            "dateSigned": "2021-03-05T00:00:00Z"
        }
    ],
    "bids": {
        "statistics": [
            {
                "id": "1",
                "measure": "bids",
                "relatedLot": "1",
                "value": 1
            }
        ]
    },
    "language": "en"
}